Two Sigma Investments’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-81,093
Closed -$4.46M 3015
2022
Q2
$4.46M Sell
81,093
-218,867
-73% -$11.5M 0.01% 832
2022
Q1
$9.61M Buy
299,960
+247,437
+471% +$7.1M 0.03% 623
2021
Q4
$1.14M Buy
52,523
+30,122
+134% +$664K ﹤0.01% 2421
2021
Q3
$491K Buy
+22,401
New +$448K ﹤0.01% 3283
2020
Q1
Sell
-2,735
Closed -$37K 4037
2019
Q4
$37K Sell
2,735
-6,219
-69% -$81.1K ﹤0.01% 3580
2019
Q3
$140K Buy
8,954
+347
+4% +$6.64K ﹤0.01% 3263
2019
Q2
$193K Buy
8,607
+7,428
+630% +$360K ﹤0.01% 3102
2019
Q1
$81K Sell
1,179
-232
-16% -$14.9K ﹤0.01% 2917
2018
Q4
$74K Buy
1,411
+58
+4% +$3.7K ﹤0.01% 2841
2018
Q3
$92K Sell
1,353
-975
-42% -$88.4K ﹤0.01% 3081
2018
Q2
$276K Buy
2,328
+1,212
+109% +$122K ﹤0.01% 2991
2018
Q1
$92K Sell
1,116
-2,161
-66% -$245K ﹤0.01% 3045
2017
Q4
$489K Buy
+3,277
New +$315K ﹤0.01% 2454

Other funds holding SRRA

Two Sigma Investments's SRRA Position: Q3 2022 in Review

Two Sigma Investments sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 81,093 shares — an estimated $4.46M sold.

Two Sigma Investments first reported a position in SRRA in Q4 2017 and held it in 13 quarters. The position peaked at $9.61M in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Two Sigma Investments reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Investments sold 81,093 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $4.46M.
  • Two Sigma Investments first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2017 and held it in 13 quarters.
  • Two Sigma Investments's Sierra Oncology, Inc. Common Stock position peaked at $9.61M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Two Sigma Investments's 13F filing for Q3 2022, filed 14 Nov 2022.